Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Exclusion Criteria

• •Known medical history of allergy, hypersensitivity, or poor tolerance to any component of DuoTrav® deemed clinically significant in the opinion of the Principal Investigator.
• •Corneal dystrophies in either eye.
• •Risk of visual field or VA worsening as a consequence of participation in the study, in the investigator's best judgment.
• •Any disease or condition that would preclude the safe administration of a topical beta-blocker, present a special risk to the subject, or interfere with optimal participation in the study.
• •Women who are pregnant or lactating.
• •Participation in any other investigational study within 30 days prior to the Screening Visit.